Lupin Limited (BOM: 500257)

Market Cap	972.69B
Revenue (ttm)	214.31B
Net Income (ttm)	26.26B
Shares Out	456.23M
EPS (ttm)	57.41
PE Ratio	37.14
Forward PE	28.68
Dividend	8.00 (0.38%)
Ex-Dividend Date	Jul 16, 2024

Volume	10,339
Average Volume	33,159
Open	2,113.45
Previous Close	2,111.80
Day's Range	2,067.00 - 2,134.40
52-Week Range	1,411.15 - 2,403.45
Beta	0.64
RSI	42.26
Earnings Date	Feb 5, 2025

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nerv...

• Industry: Pharmaceutical Preparations
• Founded: 1968
• Employees: 19,210
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500257

Financial Performance

In 2023, Lupin's revenue was 200.11 billion, an increase of 20.25% compared to the previous year's 166.42 billion. Earnings were 19.14 billion, an increase of 345.15%.